Abstract:BACKGROUND AND PURPOSE: Glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor dual agonist have promising therapeutic effects in the treatment of obesity and diabetes. Moreover, GLP-1 and cholecystokinin 2 (CCK2 ) dual agonists have been shown to restore pancreas function and improve glycaemic control in preclinical studies. We describe, for the first time, the beneficial effects of GLP-1/glucagon receptor and GLP-1/CCK2 dual agonists, which can be integrated into one peptide, resulting in significant anti-diabetes and anti-obesity effectiveness.EXPERIMENTAL APPROACH: The in vitro potency of this novel peptide Xenopus (x) GLP-1/GCG/CCK2 tri-agonist (xGLP/GCG/gastrin) against GLP-1, GCG, CCK1 and CCK2 receptors was determined on cells expressing the corresponding receptors by cAMP accumulation or ERK1/2 phosphorylation assays. The in vivo anti-diabetes and anti-obesity effects of this tri-agonist xGLP/GCG/gastrin were studied in both db/db and diet induced obesity (DIO) mice.KEY RESULTS: xGLP/GCG/gastrin was a potent and selective GLP-1, GCG and CCK2 tri-agonist. In DIO mice, the metabolic benefits of xGLP-1/GCG/gastrin, such as reduction of body weight and hepatic lipid contents were significantly better than those of the peptide ZP3022 (GLP-1/CCK-2 dual agonist) and liraglutide. In a short-term study in db/db mice, xGLP/GCG/gastrin treatment had considerable effects, increasing islet numbers, islet areas and insulin content. In a long-term treatment study using db/db mice, xGLP-1/GCG/gastrin showed a significantly and sustained improvement in glucose tolerance and glucose control compared with that of liraglutide, ZP3022, cotadutide (GLP-1/GCG dual agonist) and xGLP/GCG-15.CONCLUSIONS AND IMPLICATIONS: These results demonstrate the therapeutic potential of xGLP-1/GCG/gastrin for the treatment of obesity and diabetes.

Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism

Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism

Regulation Of Glucose Homeostasis And Lipid Metabolism By Ppp1r3g-Mediated Hepatic Glycogenesis

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

The clinical experience of GLP-1 receptor agonist drugs

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

GLP-1 and Amylin in the Treatment of Obesity

GLP-1, a powerful physiological incretin: an update.

The physiology of glucagon-like peptide 1

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Glucagon-like peptide-1 receptor agonists: Exploring the mechanisms from glycemic control to treatment of multisystemic diseases

GLP-2 regulation of intestinal lipid handling

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

A GLP‐1/glucagon/CCK‐2 receptors tri‐agonist provides new therapy for obesity and diabetes

Effects and Mechanisms of GLP-1 on Fatty Acid Metabolism in Insulin-Resistant 3T3-L1 Adipocytes

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs